Pat Cotroneo Biography and Net Worth

CFO of FibroGen

Pat Cotroneo serves as Chief Financial Officer of the Company. Mr. Cotroneo joined us in 2000 as Controller, was promoted to Vice President of Finance, and subsequently promoted to Chief Financial Officer in 2008. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. Prior to SyStemix, he was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a Bachelor of Science degree with honors from the University of San Francisco and was selected a Louise M. Davies scholar.

What is Pat Cotroneo's net worth?: The estimated net worth of Pat Cotroneo is at least $100,765.76 as of June 15th, 2021. Mr. Cotroneo owns 276,677 shares of FibroGen stock worth more than $100,766 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Cotroneo may own. Learn More about Pat Cotroneo's net worth.
How do I contact Pat Cotroneo?: The corporate mailing address for Mr. Cotroneo and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Pat Cotroneo's contact information.
Has Pat Cotroneo been buying or selling shares of FibroGen?: Pat Cotroneo has not been actively trading shares of FibroGen during the past quarter. Most recently, Pat Cotroneo sold 4,053 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $25.62, for a transaction totalling $103,837.86. Following the completion of the sale, the chief financial officer now directly owns 276,677 shares of the company's stock, valued at $7,088,464.74. Learn More on Pat Cotroneo's trading history.
Who are FibroGen's active insiders?: FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.
Are insiders buying or selling shares of FibroGen?: In the last year, FibroGen insiders bought shares 2 times. They purchased a total of 72,123 shares worth more than $121,383.91. The most recent insider tranaction occured on June, 12th when insider Deyaa Adib bought 22,123 shares worth more than $25,883.91. Insiders at FibroGen own 2.0% of the company. Learn More about insider trades at FibroGen.
Information on this page was last updated on 6/12/2024.

Pat Cotroneo Insider Trading History at FibroGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2021	Sell	4,053	$25.62	$103,837.86	276,677
12/15/2020	Sell	3,068	$43.60	$133,764.80	266,144
9/15/2020	Sell	3,070	$43.63	$133,944.10	272,226
9/3/2020	Sell	15,004	$50.91	$763,853.64	278,947
6/16/2020	Sell	3,928	$39.68	$155,863.04	271,060
3/16/2020	Sell	9,239	$26.36	$243,540.04	245,705
9/17/2019	Sell	3,201	$41.38	$132,457.38	244,432
6/18/2019	Sell	3,201	$43.12	$138,027.12	250,777
3/19/2019	Sell	7,665	$55.41	$424,717.65	239,504
2/28/2019	Sell	14,787	$60.08	$888,402.96	267,891
12/18/2018	Sell	3,330	$41.10	$136,863.00	222,004
9/13/2018	Sell	2,318	$59.50	$137,921.00	230,922
9/10/2018	Sell	1,011	$57.35	$57,980.85	220,422
6/14/2018	Sell	10,069	$59.47	$598,803.43	224,704
6/8/2018	Sell	1,011	$55.55	$56,161.05	228,034
6/4/2018	Sell	6,013	$55.16	$331,677.08	230,311
5/21/2018	Sell	14,987	$55.04	$824,884.48
3/15/2018	Sell	42,026	$52.85	$2,221,074.10	168,334
3/13/2018	Sell	5,932	$54.61	$323,946.52	168,334
3/8/2018	Sell	1,894	$53.12	$100,609.28	176,160
2/16/2018	Sell	49,500	$55.96	$2,770,020.00	207,392
1/22/2018	Sell	25,000	$48.72	$1,218,000.00	208,852
12/11/2017	Sell	2,851	$46.00	$131,146.00	183,852
9/11/2017	Sell	2,851	$49.45	$140,981.95	157,405
8/8/2017	Sell	95,000	$50.61	$4,807,950.00	173,366
8/2/2017	Sell	28,346	$33.97	$962,913.62	170,666
7/6/2017	Sell	4,000	$34.00	$136,000.00	167,366
6/22/2017	Sell	3,000	$32.00	$96,000.00	166,366
6/19/2017	Sell	5,500	$30.00	$165,000.00	168,866
6/12/2017	Sell	2,891	$28.75	$83,116.25	163,366
4/25/2017	Sell	6,500	$28.00	$182,000.00	164,405
1/11/2017	Sell	6,500	$24.00	$156,000.00	138,748
12/12/2016	Sell	2,344	$22.05	$51,685.20	132,248
9/12/2016	Sell	2,345	$18.22	$42,725.90	134,359
6/15/2016	Sell	1,796	$16.49	$29,616.04	138,114
5/16/2016	Sell	6,107	$17.60	$107,483.20	141,868
11/25/2015	Sell	5,000	$30.00	$150,000.00	107,775
9/15/2015	Sell	1,093	$27.95	$30,549.35	107,498
9/10/2015	Sell	7,500	$27.33	$204,975.00	107,251
7/20/2015	Sell	7,881	$23.47	$184,967.07

Pat Cotroneo Buying and Selling Activity at FibroGen

FibroGen Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Today's Range

Now: $0.36

$0.34

$0.38

50 Day Range

MA: $0.36

$0.30

$0.47

2 Week Range

Now: $0.36

$0.18

$2.93

Volume

730,117 shs

Average Volume

2,207,854 shs

Market Capitalization

$36.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>